Products for Research Use Only
RegisterLogin

Montelukast

CAT: 0804-HY-13315A-01Size: 50 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-13315A-01Size:50 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Montelukast (MK0476 free base) is a potent, selective and orally active antagonist of cysteinyl leukotriene receptor 1 (CysLT1) . Montelukast can be used for the reseach of asthma and liver injury. Montelukast also has an antioxidant effect in intestinal ischemia-reperfusion injury, and could reduce cardiac damage. Montelukast decreases eosinophil infiltration into the asthmatic airways. Montelukast can also be used for COVID-19 research[1][2][3][4].
CAS Number
158966-92-8
Product Name Alternative
MK0476 (free base)
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Leukotriene Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
https://www.medchemexpress.com/montelukast.html
Purity
99.94
Solubility
DMSO : 233.33 mg/mL (ultrasonic)
Smiles
O=C(O)CC1(CS[C@@H](C2=CC=CC(/C=C/C3=NC4=CC(Cl)=CC=C4C=C3)=C2)CCC5=CC=CC=C5C(C)(O)C)CC1
Molecular Formula
C35H36ClNO3S
Molecular Weight
586.18
Precautions
H302, H312, H332
References & Citations
[1]Pu S, et, al. Montelukast Prevents Mice Against Acetaminophen-Induced Liver Injury. Front Pharmacol. 2019 Sep 18; 10:1070.|[2]William RHJ, et, al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am J Respir Crit Care Med. 2002 Jan 1; 165 (1) : 108-16.|[3]Langlois A, et al. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol. 2006;118 (1) :113-119.|[4]Khan AR, et al. Montelukast in hospitalized patients diagnosed with COVID-19. J Asthma. 2022 Apr;59 (4) :780-786.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
LTD4/CysLT1
Citation 01
Adv Mater. 2024 Jun;36 (24) :e2311760.|Anal Chem. 2025 Nov 18;97 (45) :25158-25167.|Cell Rep. 2025 Apr 16;44 (5) :115572.|Nat Commun. 2025 Apr 3;16 (1) :3177.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug;396 (8) :1759-1771.|Patent. US20210309696A1.|Patent. US20230348536A1.|SSRN. 2024 Oct 29.|Artif Cell Nanomed B. 2019 Dec;47 (1) :4234-4239.|Eur J Pharmacol. 2022 May 15;923:174892.|J Cachexia Sarcopenia Muscle. 2022 Aug;13 (4) :2242-2253.|Patent. US20230404992A1.

Alternative Products

CatalogName
FM137467-01Montelukast
RM-M201233-01Montelukast EP Impurity A; ent-Montelukast
B1792-250Montelukast Sodium
FM44625-01Montelukast styrene
T71369-01Montelukast sulfoxide
454519-01Methoxy Montelukast
MBS6014680-01Montelukast Sulfone

Popular Products